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Abstract: This study investigated the possible antinociceptive effect of p-cymene 
in different tests of orofacial nociception. The animals (mice) were pretreated (i.p.) 
with p-cymene (25, 50, 100 mg/kg), morphine (5 mg/kg), or vehicle (0.2% Tween 
80+saline), and were then subsequently administered, subcutaneously into their 
upper lip: formalin, capsaicin, and glutamate. The nociceptive behavior response 
was characterized by the time in s that the mice remained rubbing the orofacial 
region, for a period of 40 min in the formalin test (first phase, 0-6 min; and second 
phase, 21-40 min), and for 42 and 15 min in the capsaicin and glutamate tests, 
respectively. To verify the possible opioid involvement in the antinociceptive effects, 
naloxone (i.p.) was administered into the mice 15 min prior to the pretreatment with 
p-cymene (100 mg/kg). Finally, whether or not the p-cymene evoked any change in 
motor performance in the Rota-rod test was evaluated. The results showed that the 
treatment with p-cymene, at all doses, reduced (p<0.001) the nociceptive behavior 
in all nociception tests. The antinociceptive effect of p-cymene was antagonized 
by naloxone (1.5 mg/kg). Additionally, mice treated with p-cymene did not show 
any change in motor performance. In conclusion, p-cymene attenuated orofacial 
nociception, suggesting an involvement of the opioid system in this effect. Thus, 
p-cymene might represent an important biomolecule for management and/or 
treatment of orofacial pain.
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Introduction
 Orofacial pain accounts for over 25% of 
all complaints in respect to pain (Sessle, 1987). 
Orofacial pain refers to conditions related to oral and 
face structures (Lipton et al., 1993), and stands out 
from other somatic pain due to its high intensity and 
prevalence, which often prevents an individual from 
performing his/her daily activities normally (Barros et 
al., 2009).
 A variety of drugs are used for the 
pharmacological treatment of orofacial pain, such as 
the opioid and non-opioid analgesics, non-steroidal 
anti-inflammatory drugs (NSAID), corticosteroids, 
anxiolytics, antidepressants, and anticonvulsants 
(Dionne, 2001), but the side effects and high costs of 
these drugs have led to a constant search for alternative 
drugs from medicinal plants with analgesic and anti-
inflammatory properties.
 p-Cymene (p-isopropyltoluene, 1) is a 
monoterpene biological precursor of carvacrol and one 
of the main constituents of the essential oil from species 
of Protium, with more than 80% of these species found 
in the Amazon region (Siani et al., 1999). Recent studies 
have shown that species such as Protium heptaphyllum 
(Aubl.) Marchand, P. kleinii Cuatrec., Burseraceae, 
Hyptis pectinata (L.) Poit., Lamiaceae and Zataria 
multiflora Boiss., Lamiaceae, rich in p-cymene, show 
antinociceptive activity in rodents (Oliveira et al., 
2005; Otuki et al., 2001; Bispo et al., 2001; Ramezani 
et al., 2004).
1
 In addition, other monoterpenes such as 
menthol, linalool, citronellal, and carvone have shown 
antinociceptive activity in animal models of nociception 
(Melo et al., 2010; Galeotti et al., 2002; Peana et al., 
2006; Gonçalves et al., 2008; Quintans-Júnior et al., 
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2010).
 Since p-cymene-containing natural products 
and others monoterpenes have been used by to 
alleviate pain and inflammation-related processes it 
is believed that p-cymene can be an effective agent in 
the management of orofacial pain. With this in mind, 
this study investigated the antinociceptive potential of 
p-cymene in models of orofacial nociception induced 
by formalin, capsaicin, and glutamate.
Material and Methods
Drugs
 For the experiments the following drugs 
were used: p-cymene (99.7% purity; Sigma, USA), 
morphine hydrochloride (Merck, Brazil), naloxone 
(Res. Biochemicals Inc., USA), formaldehyde PA 
(Reagen, Brazil), capsaicin (Sigma, USA), diazepam 
(União Química, Brazil). Vehicle was 0.2% Tween 80 
(Sigma, USA) dissolved in saline.
Animals 
 The experiments were performed with male 
Swiss mice (25-30 g), from the Central Animal Facility of 
the Federal University of Sergipe. The animals were kept 
four to five per cage (41 x 34 x 18 cm), at a temperature 
of 22-24 oC, in a light controlled room (12 h/12 h light/
dark cycle, lights on at 6:00 a.m.), with water and food 
ad libitum. All procedures were in compliance with the 
guidelines of the International Association for the Study of 
Pain (IASP) (Zimmermann, 1983) and were approved by 
the Ethics Committee on Animal Care at UFS (Protocol N° 
03/2009).
Experimental nociceptive tests 
  
 Formalin test 
 The induction of nociception in the orofacial 
formalin test was done by subcutaneous injection of 
formalin (20 μL, 2%) into the upper lip of mice (n=8/
group) according to previous studies (Luccarini et al., 
2006). The administration of formalin in the orofacial 
region induces a biphasic behavioral response (Cadet et 
al., 1993). The first phase (Phase 1) occurs within 0-5 min 
after administration of the nociceptive substance; this 
phase is followed by a latency period of about 10 min. 
Then, a second phase (Phase 2) occurs with duration of 
about 25 min (15 to 40 min). The nociceptive behavior 
assessed during the two phases was the time that the 
animals remained rubbing the orofacial region.
 The animals were pretreated systemically 
(intraperitoneal route) with vehicle (0.2% Tween 
80+saline), p-cymene (25, 50, 100 mg/kg), and 
morphine (5 mg/kg) 30 min before injection of formalin. 
The possible involvement of the opioid system in the 
antinociception produced by p-cymene was tested by 
administration of naloxone (1.5 mg/kg), an opioid 
antagonist, 30 min before administration of the above 
mentioned drugs.
Capsaicin test 
 This orofacial nociception test was induced by 
subcutaneous administration of capsaicin as described 
previously by Pellisier (Pellisier et al., 2002). Mice 
(n=8) received a subcutaneous injection of capsaicin 
(20 μL, 2.5 μg diluted in DMSO 25% in distilled water) 
into the upper lip. In pilot studies performed in our 
laboratory, the animals showed the behavior of rubbing 
the orofacial region with greater intensity for a period 
of 42 min after the injection of capsaicin. Therefore, 
the quantification of nociception was performed 
during this period, measuring the time (s) that the 
animals exhibited the nociceptive behavior of rubbing 
the orofacial region with the hind or front paw. The 
p-cymene, morphine, and vehicle were administered in 
a similar manner and at the same doses as the previous 
test.
 Glutamate test 
 This orofacial nociception test was induced by 
subcutaneous administration of glutamate into the upper 
lip of mice as described previously by Quintans-Júnior 
et al. (2010). Mice were divided into five groups (n=8) 
and treated intraperitoneally with vehicle, p-cymene 
(25, 50, 100 mg/kg), or morphine 30 min before the 
injection of 40 μL of a glutamate (25 mM) solution in the 
upper lip. Then, the animals were observed for a period 
of 15 min, starting immediately after the injection of the 
glutamate. The quantification of nociceptive response 
was performed during this period, measuring the time 
(s) that the animals exhibited the behavior of rubbing 
the orofacial region with the hind or front paw.
Motor performance test
 Rota-rod test 
 To assess the possible interference of p-cymene 
on animal motor performance, the rota-rod test was 
performed. Initially, the mice able to stay on the rota-
rod for more than 180 s (7 rpm) were selected 24 h 
before the experiment. Then, the animals were divided 
into five groups (n=8), with which we performed the 
following treatments: p-cymene (25, 50, 100 mg/kg, 
i.p.), vehicle (control), and diazepam (1.5 mg/kg, i.p.); 
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after 30, 60, and 120 min each animal was submitted 
to the rota-rod and the results are expressed as the time 
(s) the animals remained on the rotating rod after the 
treatments mentioned above. The maximum time of 
permanence of the animal on the rota-rod was 180 s.
Statistical analysis
 Data were analyzed using GraphPad Prism 
3.0 Software. Analysis of variance (ANOVA) was 
performed, followed by Dunnet's and Tukey’s post-
test to determine, respectively, which doses differed 
statistically from the control group and among them. 
For all tests the level of significance was set at 5%.
Results
Formalin test
 The results showed that pretreatment with 
p-cymene (at all doses tested) and morphine produced 
antinociception, evidenced by a statistically significant 
difference (p<0.001) for the time that the animal 
remained rubbing the orofacial region, in both phases 
of testing (Figure 1). It was also demonstrated that 
naloxone (1.5 mg/kg, i.p.) reversed the antinociception 
induced by morphine and p-cymene (100 mg/kg) in 
both phases of testing.
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Figure 1. Effect of pretreatment of animals with vehicle, 
p-cymene (25, 50 and 100 mg/kg) or morphine (5 mg/kg) 
in the nociception induced by formalin. A indicates the first 
phase (0 to 5 min) and B the second phase (15 to 40 min) of 
formalin test ***p<0.001 represents significant differences 
when compared to the control group (ANOVA followed by 
Dunnett). #p<0.001 indicates significant difference compared 
with morphine and &p<0.001 compared with the p-cymene 
(100 mg/kg), (ANOVA followed by Tukey).
Capsaicin test
 According to Figure 2, the pretreatment with 
p-cymene caused a statistically significant decrease 
(p<0.001) of nociceptive behavior induced by 
administration of capsaicin at all doses (25, 50, and 100 
mg/kg). The effect of the highest dose was similar to 
morphine.
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Figure 2. Effect of pretreatment of animals with vehicle, 
p-cymene (25, 50 and 100 μg/kg) or morphine (5 mg/kg) in 
the nociception induced by injection of capsaicin (20 μL) in 
the orofacial region (n=8). ***p<0.001 represents significant 
differences when compared to the control group (ANOVA 
followed by Dunnett). 
Glutamate test
 Systemic treatment of animals with p-cymene, 
at doses of 25, 50, and 100 mg/kg significantly reduced 
the nociception induced by administration of glutamate 
in the upper lip (Figure 3).
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Figure 3. Effect of pretreatment of animals with vehicle, 
p-cymene (25, 50 and 100 mg/kg) in the nociception induced 
by injection of glutamate (40 μL/25 mM) in the orofacial 
region (n=8). **p<0.01 ***p<0.001 represents significant 
differences when compared to the control group (ANOVA 
followed by Dunnett).
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Rota-rod test 
 Pretreatment of mice with p-cymene (25, 50, 
and 100 mg/kg) or vehicle did not induce changes in 
motor performance, since the animals remained on the 
rotating rod for 180 s at 30, 60, and 120 min (data not 
shown in figure). As expected, diazepam (1.5 mg/kg), 
a CNS depressant drug, reduced the latency time of 
falling at 30, 60, and 120 min. 
Discussion
 This study demonstrated the antinociceptive 
effect of p-cymene by behavioral tests of nociception 
(formalin, capsaicin, and glutamate tests) in mice. The 
use of formalin in the orofacial region induces a biphasic 
nociceptive response (Luccarini et al., 2006). The first 
phase (0-5 min) corresponds to the direct stimulation 
of nociceptors, predominantly C fibers, with the 
participation of substance P, bradykinin, and glutamate 
(Shibata et al., 1989). This phase is only sensitive to 
analgesics acting on the CNS (Hunskaar et al., 1985). 
The first phase is followed by an interphase, which lasts 
about fifteen minutes and results from active inhibition 
of the excitability of nociceptors (Tjolsen et al., 1992). 
The second phase, which starts twenty-one min after 
formalin injection, is derived from two components: 
central sensitization of nociceptors and second order 
neurons, and the action of inflammatory mediators 
such as histamine, serotonin (5-HT), bradykinin, and 
prostaglandins released as a result of tissue injury 
(Henry et al., 1999). This second phase of nociception 
could be inhibited by both NSAID and opioid drugs 
(Hunskaar et al., 1985). The results of the present 
study showed that p-cymene significantly reduced the 
nociceptive behavior in the 1st and 2nd phases of the 
formalin test, suggesting therefore an action in both 
neurogenic and inflammatory pain. It was also verified 
that the non-selective opioid antagonist naloxone 
reversed the antinociceptive effect of p-cymene (100 
mg/kg), suggesting an effect mediated by the opioid 
system.
 Just as formalin, capsaicin is also an important 
irritant used to induce nociception. Capsaicin is used 
as a pharmacological tool for the study of nociception 
through direct activation of nociceptive fibers, especially 
type C (Sakurada et al., 1992). Capsaicin applied to skin, 
muscle, and other tissues has been shown to produce 
inflammation, to activate and to sensitize trigeminal 
and spinal small-diameter nociceptive afferents, as 
well as dorsal horn neurons. It also evokes nociceptive 
behavior in animals and intense pain, hyperalgesia, and 
referred pain in humans (Hu et al., 2005; Lam et al., 
2009a; Lam et al., 2009b).
 The activation of nociceptors by capsaicin 
occurs through its binding to vanilloid receptors 
(TRPV1), which induces the influx of cations 
producing depolarization and excitation of neurons that 
cause the release of neuropeptides such as tachykinins, 
substance P, calcitonin gene-related peptide, excitatory 
amino acids (aspartate and glutamate), nitric oxide, 
and proinflammatory mediators from the peripheral 
terminals (Sakurada et al., 1992). In this context, the 
antinociceptive effect observed for p-cymene in the 
capsaicin test may be a result of its possible inhibition 
of neurotransmitters involved in activation of sensory 
fibers responsible for transmission of nociceptive 
stimuli.
 A number of monoterpenes have also been 
described as agonists or antagonists of different 
members of the TRPV channel family (Xu et al., 2005; 
2006; Vogt-Eisele et al., 2007). The ability of camphor, 
a naturally occurring monoterpene produced by 
Camphor Laurel (Cinnamomum camphora), to modulate 
sensations of warmth in humans has been attributed to 
its ability to activate TRPV3 (Moqrich et al., 2005). 
TRPV3 is expressed in keratinocytes, the dorsal root 
ganglia, the brain, and spinal cord (Vogt-Eisele et 
al., 2007). It has been implicated in hyperalgesia, 
inflamed tissues, and possibly skin sensitization (Xu 
et al., 2005). Vogt-Eisele et al. (2007) demonstrated 
that some of the effects described for the terpenoids 
may be related to the activation of vanilloid receptors. 
The mechanism of action of camphor, menthol, thymol, 
and carvacrol, for example, is related to activation of 
TRPV3 receptors. p-Cymene did not significantly 
activate these receptors. 
 Glutamate is present in both central and 
peripheral terminals of trigeminal and dorsal root 
ganglion neurons. Noxious stimulation of primary 
afferent fibers results in the release of glutamate from 
the peripheral as well as central terminals of trigeminal 
and spinal afferent fibers (Keast & Stephensen, 2000; 
Lam et al., 2005). In addition, glutamate injection 
into the rat masseter muscle or temporomandibular 
joint (TMJ) reflexly evokes a dose-dependent increase 
in jaw muscle electromyographic (EMG) activity 
(Cairns et al., 1998; Cairns et al.,  2001a; Cairns et 
al., 2001b, Cairns et al., 2002) and central sensitization 
of trigeminal brainstem nociceptive neurons (Lam et 
al., 2009b). Similarly, glutamate injection into the 
human masseter muscle causes pain and mechanical 
hyperalgesia that may be attenuated by co-injection of 
a NMDA receptor antagonist (Cairns et al., 1998).
 This nociceptive response caused by glutamate 
seems to involve peripheral, spinal, and supra-spinal 
sites, and its action is mediated by NMDA (N-methyl-
D-aspartate) and non-NMDA receptors (Beirith et 
al., 2002). Several studies have demonstrated that 
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The impact of orofacial pain on the quality of life of 
patients with temporomandibular disorder. J Orofac 
Pain 23: 28-37.
Batista PA, Werner MFP, Oliveira EC, Burgos L, Pereira 
P, Brum LF, Santos AR 2008. Evidence for the 
involvement of ionotropic glutamatergic receptors 
on the antinociceptive effect of (-)-linalool in mice. 
Neurosci Lett 440: 299-303.
Beirith A, Santos AR, Calixto JB 2002. Mechanisms 
underlying the nociception and paw oedema caused 
by injection of glutamate into the mouse paw. Brain 
Res 924: 219-228.
Bispo MD, Mourão RHV, Franzotti EM, Bomfim KBR., 
Arrigoni-Blank MF, Moreno MPN, Marchioro 
M, Antoniolli AR 2001. Antinociceptive and 
antiedematogenic effects of the aqueous extract of 
Hyptis pectinata leaves in experimental animals. J 
Etnopharmacol 76: 81-86.
Cadet R, Aigouv L, Woda A 1993. Sustained hyperalgesia can 
be induced in the rat by a single formalin injection and 
depends on the initial nociceptive inputs. Neurosci 
Lett 156: 43-46.
Cairns BE, Sessle BJ, Hu JW 1998. Evidence that excitatory 
amino acid receptors within the temporomandibular 
joint region are involved in the reflex activation of the 
jaw muscles. J Neurosci 18: 8056-8064.
Cairns BE, Sessle BJ, Hu JW 2001a. Characteristics of 
glutamate-evoked temporomandibular joint afferent 
activity in the rat. J Neurophysiol 85: 2446-2454.
Cairns BE, Hu JW, Arendt-Nielsen L, Sessle BJ, Svensson P 
2001b. Sex-related differences in human pain and rat 
afferent discharge evoked by injection of glutamate 
into the masseter muscle. J Neurophysiol 86: 782-
791.
Cairns BE, Gambarota G, Svensson P, Arendt-Nielson L, 
Berde CB 2002. Glutamateinduced sensitization of rat 
masseter muscle fibers. Neuroscience 109: 389-399.
Coggeshall RE, Carlton SM 1997. Receptor localization 
in the mammalian dorsal horn and primary afferent 
neurons. Brain Res Rev 24: 28-66.
De Sousa DP, Gonçalves JCR, Quintans-Júnior LJ, Cruz 
JS, Araújo DAM, Almeida RN 2006. Study of 
anticonvulsant effect of citronellol, a monoterpene 
alcohol, in rodents. Neurosci Lett 401: 231-235.
Dionne RA 2001. Pharmacologic advances in orofacial pain: 
from molecules to medicine. J Dent Educ 65: 1393-
1403.
Ferreira J, Santos ARS, Calixto JB 1999. The role of systemic, 
spinal and supraspinal L-argininenitric oxide-cGMP 
pathway in thermal hyperalgesia caused by intrathecal 
injection of glutamate in mice. Neuropharmacol 38: 
835-842.
Galeoti N, Mannelli LC, Mazzanti G, Bartolini A, Ghelardini 
C 2002. Menthol: a natural analgesic compound. 
Neurosci Lett 322: 145-148.
Gonçalves JCR, Oliveira FS, Benedito RB, Sousa DP, 
Almeida RN, Araújo DAM 2008. Antinociceptive 
activity of (-)-carvone: evidence of association with 
decreased peripheral nerve excitability. Biol Pharm 
Bull 31: 1017-1020.
Henry JL, Yaspal K, Picher GM, Chabot JG, Coderre TJ 
the excitatory amino acid receptors are involved in 
nociceptive primary afferent transmission, both in 
the development and maintenance of painful response 
(Coggeshall & Carlton, 1997). Thus, the suppression 
of glutamate-induced nociception by p-cymene 
treatment can be associated with its interaction with 
the glutamatergic system (Ferreira et al., 1999). Batista 
et al. (2008) demonstrated that linalool, a monoterpene 
compound prevalent in the essential oils of various 
aromatic plant species, possesses antinociceptive 
properties in mice. This effect involves peripheral 
and spinal sites of action and seems to be mediated by 
interaction with ionotropic glutamatergic-dependent 
mechanisms, via NMDA receptors. 
 Previous studies have suggested that the CNS 
depression and the nonspecific muscle relaxation effect 
can reduce the response of motor coordination and might 
invalidate the behavior tests’ results (Almeida et al., 
2004; De Sousa et al., 2006). Our results revealed that 
all mice treated with p-cymene, at the doses evaluated, 
did not have any performance alteration in the Rota-
rod test. In addition, visually as well, there has been 
no interference with motor coordination of animals, 
thus eliminating a nonspecific muscle-relaxing effect 
of p-cymene. 
Conclusions
 Based on our results, the monoterpene 
p-cymene proved to have antinociceptive activity that 
does not interfere with motor coordination of animals, 
and this pharmacological action may modulate both 
neurogenic and inflammatory pain. Additionally, it 
seems, at least in part, that the antinociceptive action 
of p-cymene involves the opioid system. These 
results suggest and support the use of p-cymene as a 
promising substance for the management of orofacial 
pain; however, further studies are necessary to prove its 
mechanism of action.
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